2. Neuronal Signaling Protein Tyrosine Kinase/RTK
  3. Trk Receptor
  4. DS002

DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy.

For research use only. We do not sell to patients.

DS002

DS002 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

DS002 Related Antibodies

Top Publications Citing Use of Products

View All Trk Receptor Isoform Specific Products:

View All Isoforms
TrkA TrkB TrkC Trk

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy[1][2].

Species Reactivity

Human
IC50 & Target[2]

TrkA

 

In Vitro

DS002 potently blocks the binding of human NGF to TrkA in cell-free competitive ELISA assays, with an IC50 of 6.6 nM[2].
DS002 (0.001-100 nM) binds to human, rat and mouse NGF with high affinity in cell-free ELISA assays, with corresponding EC50 values of 0.031 nM, 0.086 nM and 0.036 nM[2].
DS002 (1.5625-100 nM) exhibits ultrahigh binding affinity (KD <1 pM) for human NGF and high binding affinity (KD values of 149 pM and 582 pM, respectively) for rat and mouse NGF in cell-free BLI assays[2].
DS002 potently blocks the binding of rat and mouse NGF to TrkA in cell-free competitive ELISA assays, with IC50 values of 1.98 nM and 8.46 nM, respectively[2].
DS002 inhibits NGF-induced TF-1 cell proliferation in a dose-dependent manner by blocking the TrkA-mediated downstream signaling pathway in cell-based in vitro assays[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DS002 Related Antibodies
In Vivo

DS002 (0.1-2.5 mg/kg; subcutaneous injection; administered on days -3 to 9) exerts a significant preventive effect against Paclitaxel (HY-B0015)-induced mechanical allodynia, while doses of 0.5 and 2.5 mg/kg alleviate Paclitaxel-induced cold allodynia in rats[2].
DS002 (0.02-0.5 mg/kg; subcutaneous injection; administered on days -3 to 16) exerts a significant preventive effect against Cisplatin (HY-17394)-induced mechanical hyperalgesia in rats[2].
DS002 (0.5-2.5 mg/kg; subcutaneous injection; administered on days -3 to 3) exerts a significant preventive effect on mechanical and cold allodynia induced by Vincristine (HY-N0488A) in rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (SD) (male, 200-220 g starting weight, paclitaxel-induced CIPN model)[2]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
Administration: s.c.; administered on days -3, 3, 9
Result: Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 14.
Decreased acetone-induced pain scores and foot withdrawal frequency drastically compared to vehicle control on day 15 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
Animal Model: Sprague-Dawley (SD) (male, 200-220 g starting weight, cisplatin-induced CIPN model)[2]
Dosage: 0.02 mg/kg; 0.5 mg/kg
Administration: s.c.; administered on days -3, 3, 9, 16
Result: Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 21.
Showed no analgesic effect on cold allodynia due to unsuccessful model establishment.
Caused no weight loss in treated rats.
Animal Model: Sprague-Dawley (SD) (male, 200-220 g starting weight, vincristine-induced CIPN model)[2]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
Administration: s.c.; administered on days -3, 3
Result: Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 7 (0.5 mg/kg and 2.5 mg/kg doses).
Reduced acetone-induced pain scores and foot withdrawal frequency compared to vehicle control on day 8 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
Gene ID

4803  [NCBI]

Accession
Target

NGF/bNGF
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DS002 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DS002DS 002DS-002Trk ReceptorTropomyosin related kinase receptorchemotherapy-induced peripheral neuropathyhuman NGFchronic painrat NGFNerve Growth FactorTrkA-mediated downstream signaling pathwaysmouse NGFaromatic amino acid metabolic pathwaysTrkATF-1 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DS002
Cat. No.:
HY-P992345
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.